UBRELVY is well established and tolerable—for patients taking both doses1
Adverse reactions occurring in at least 2% and at a frequency greater than placebo1
|UBRELVY 50 mg
|UBRELVY 100 mg
Table includes ARs from ACHIEVE I and II.
UBRELVY IS THE ONLY GEPANT WITH AN OPTIONAL SECOND DOSE.1,4
Migraine attacks can be unpredictable and no two attacks are the same.5
Patients can take an additional dose of UBRELVY at least 2 hours after the initial dose—there are no medication overuse headache warnings or precautions. The maximum UBRELVY dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.1